Novo Nordisk has launched the first GLP-1 weight-loss pill in the US.
The once-daily Wegovy pill costs far less than injectable versions.
Self-paying patients can buy the starting dose for $149 per month.
Higher doses will rise to between $199 and $299 monthly later this year.
The pill offers a needle-free alternative and broader patient appeal.
US approval came just before Christmas, with rollout now under way nationwide.
Novo hopes the pill will regain market share after recent profit warnings.
Shares rose on launch news despite intense competition from Eli Lilly.
Eli Lilly is developing a rival obesity pill with capped pricing plans.
UK regulators are reviewing Wegovy pill approval later this year.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
The Mundo Post delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us: